Quick Answer
SkinHealth Systems Inc. reported Cash and Equivalents of $523.02 million for fiscal year 2023.
SkinHealth Systems Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $523.02M | -8.0% |
| 2022 | $568.20M | -37.0% |
| 2021 | $901.89M | +9407.5% |
| 2020 | $9.49M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $559.44M | -18.2% | +1.8% |
| June 30, 2023 | $549.73M | -33.0% | +3.3% |
| March 31, 2023 | $532.28M | -38.1% | -6.3% |
| December 31, 2022 | $568.20M | -37.0% | -17.0% |
| September 30, 2022 | $684.21M | -4.8% | -16.7% |
| June 30, 2022 | $820.97M | +709.1% | -4.5% |
| March 31, 2022 | $859.24M | +31109.2% | -4.7% |
| December 31, 2021 | $901.89M | +9407.5% | +25.5% |
- SkinHealth Systems Inc. showed a decrease of -8.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2023 period, SkinHealth Systems Inc.’s cash and equivalents has grown by 5413.7% (from $9.49 million to $523.02 million).
- The most recent figure is from SkinHealth Systems Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 12, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: